These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 16538801)

  • 41. The use of experimental drugs during national crisis.
    Shamoo AE; Campbell JD
    Account Res; 2003; 10(1):69-84. PubMed ID: 14552302
    [No Abstract]   [Full Text] [Related]  

  • 42. Medical experimentation concerning chemical and biological weapons for mass destruction.
    Deutsch E
    Law Rev; 2003 Apr; 34(1):157-66. PubMed ID: 16211734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experimental drugs are linked to ills of Gulf War veterans.
    Leary WE
    N Y Times Web; 1994 May; ():12. PubMed ID: 11647031
    [No Abstract]   [Full Text] [Related]  

  • 44. Critics claim even babies could be exposed to pesticides in research.
    Maloney DM
    Hum Res Rep; 2005 Aug; 20(8):1-2. PubMed ID: 16320460
    [No Abstract]   [Full Text] [Related]  

  • 45. Is it time to abandon FDA's no release from liability regulation for clinical studies?
    Winter JD
    Food Drug Law J; 2008; 63(2):525-36. PubMed ID: 18561476
    [No Abstract]   [Full Text] [Related]  

  • 46. Human subjects in weapons research.
    Caplan AL; Sankar P
    Science; 2002 Nov; 298(5595):923. PubMed ID: 12411671
    [No Abstract]   [Full Text] [Related]  

  • 47. Human experimentation at the brink of life.
    Oliver AA
    GMU Law Rev; 2001; 9(4):1177-203. PubMed ID: 15233133
    [No Abstract]   [Full Text] [Related]  

  • 48. War on terror. Epidemic threats.
    Cowley G
    Newsweek; 2001 Oct; 138(18):40-1. PubMed ID: 11699429
    [No Abstract]   [Full Text] [Related]  

  • 49. An ethicist's perspective on human radiation tests.
    Graber GC
    Forum Appl Res Public Policy; 1997; 12(3):115-21. PubMed ID: 12962098
    [No Abstract]   [Full Text] [Related]  

  • 50. [Update on biological weapons and bioterrorism. Important that health services pay attention to unusual events].
    Roffey R; Lantorp K; Tegnell A; Elgh F
    Lakartidningen; 2001 Dec; 98(50):5746-8, 5751-2. PubMed ID: 11789096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Remember Saddam's human guinea pigs.
    Moreno JD
    Am J Bioeth; 2003; 3(3):W-IF4. PubMed ID: 14735883
    [No Abstract]   [Full Text] [Related]  

  • 52. Balancing pluralism and the common good: a look at open-air experiments of biowarfare agents.
    Trotter G
    Account Res; 2003; 10(2):109-21. PubMed ID: 14577423
    [No Abstract]   [Full Text] [Related]  

  • 53. Why wasn't an investigational new drug (IND) application required before appropriate study?
    Maloney DM
    Hum Res Rep; 2004 Mar; 19(3):6-7. PubMed ID: 15139342
    [No Abstract]   [Full Text] [Related]  

  • 54. Nontherapeutic research with children: the virtues and vices of legal uncertainty.
    Smolin DM
    Cumberland Law Rev; 2002-2003; 33(3):621-45. PubMed ID: 15378825
    [No Abstract]   [Full Text] [Related]  

  • 55. Cold war at Porton Down: informed consent in Britain's biological and chemical warfare experiments.
    Schmidt U
    Camb Q Healthc Ethics; 2006; 15(4):366-80. PubMed ID: 17066763
    [No Abstract]   [Full Text] [Related]  

  • 56. Proliferation of biological weapons: challenges and responses.
    Millett PD
    Med Confl Surviv; 2004; 20(1):4-18. PubMed ID: 15015544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. School vaccination requirements: historical, social, and legal perspectives.
    Hodge JG; Gostin LO
    KY Law J; 2001-2002 Summer; 90(4):831-90. PubMed ID: 15868682
    [No Abstract]   [Full Text] [Related]  

  • 58. Policies in place throughout the world: action by the European Union.
    Gouvras G
    Int J Infect Dis; 2004 Oct; 8 Suppl 2():S21-30. PubMed ID: 15491872
    [No Abstract]   [Full Text] [Related]  

  • 59. Our first line of defense against bioterrorism part 2.
    Simpson RL
    Nurs Manage; 2002 May; 33(5):10, 11. PubMed ID: 12006878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.